How have ARTH shares performed in 2024?

Arch Therapeutics' stock was trading at $7.24 on January 1st, 2024. Since then, ARTH stock has decreased by 85.5% and is now trading at $1.05. View the best growth stocks for 2024 here .

When is Arch Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ARTH earnings forecast .

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics, Inc. (OTCMKTS:ARTH) released its quarterly earnings data on Tuesday, February, 20th. The biotechnology company reported ($0.57) earnings per share for the quarter. The biotechnology company had revenue of $0.05 million for the quarter.

What other stocks do shareholders of Arch Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arch Therapeutics investors own include Anavex Life Sciences (AVXL) , POET Technologies (POETF) , Aptose Biosciences (APTO) , Inovio Pharmaceuticals (INO) , Actinium Pharmaceuticals (ATNM) , SCYNEXIS (SCYX) , Bellerophon Therapeutics (BLPH) , Sorrento Therapeutics (SRNE) , Biocept (BIOC) and Aurinia Pharmaceuticals (AUPH) .

How do I buy shares of Arch Therapeutics?

Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:ARTH

Arch Therapeutics (ARTH) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free ARTH Stock Alerts

$1.05

-0.13 (-11.02%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.05
▼
$1.22
50-Day Range: $1.12
▼
$3.09
52-Week Range: $0.39
▼
$18.00

Volume: 10,732 shs
Average Volume: 6,146 shs
Market Capitalization: $4.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials Headlines SEC Filings Short Interest

Get Arch Therapeutics alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Arch Therapeutics Stock (OTCMKTS:ARTH)

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

ARTH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ARTH Stock News Headlines

April 12, 2024 | americanbankingnews.com

Arch Therapeutics (OTCMKTS:ARTH) Shares Pass Below 50-Day Moving Average of $2.23

February 8, 2024 | msn.com

Arch Therapeutics Secures $750K Prepayment for Stock

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

January 6, 2024 | morningstar.com

Arch Therapeutics Inc ARTH

November 23, 2023 | msn.com

Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?

November 9, 2023 | finanznachrichten.de

Arch Therapeutics, Inc.: Arch Therapeutics Provides Year End Operational Update

November 9, 2023 | finance.yahoo.com

Arch Therapeutics Provides Year End Operational Update

November 2, 2023 | finance.yahoo.com

Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

September 13, 2023 | finance.yahoo.com

Arch Therapeutics Provides AC5® Commercialization Update

September 8, 2023 | finanznachrichten.de

Arch Therapeutics, Inc.: Arch Therapeutics Completes Financing as Bridge to Uplisting

September 7, 2023 | finance.yahoo.com

Arch Therapeutics Completes Financing as Bridge to Uplisting

July 8, 2023 | health.usnews.com

Dr. Arth Patel

June 13, 2023 | travel.usnews.com

Double Arch

April 25, 2023 | finance.yahoo.com

Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)

April 5, 2023 | finance.yahoo.com

Dedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In Effect

March 20, 2023 | investing.com

Arch Therapeutics Inc (ARTHD)

March 9, 2023 | finance.yahoo.com

Arch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services

March 7, 2023 | finance.yahoo.com

Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities

February 23, 2023 | benzinga.com

Arch Therapeutics Inc Stock (OTC:ARTHD), Earnings Estimates, EPS, and Revenue

January 24, 2023 | msn.com

Wound products developer Arch Therapeutics files for uplisting, $35M offering (update)

January 18, 2023 | finanznachrichten.de

Arch Therapeutics, Inc.: Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange

January 18, 2023 | finance.yahoo.com

Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System

January 17, 2023 | finance.yahoo.com

Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange

December 5, 2022 | finance.yahoo.com

The Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound System

October 20, 2022 | seekingalpha.com

ARTH Arch Therapeutics, Inc.

October 18, 2022 | yahoo.com

Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Fall

See More Headlines

Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/20/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: OTCMKTS:ARTH
Previous Symbol: NASDAQ:ARTH
CUSIP: N/A
CIK: 1537561
Web: www.archtherapeutics.com
Phone: (617) 431-2313
Fax: N/A
Employees: 8
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,980,000.00
Net Margins: -6,809.45%
Pretax Margin: -6,808.58%
Return on Equity: N/A
Return on Assets: -386.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.16
Quick Ratio: 0.04

Sales & Book Value

Annual Sales: $80,000.00
Price / Sales: 69.92
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($2.43) per share
Price / Book: -0.49

Miscellaneous

Outstanding Shares: 4,740,000
Free Float: 4,529,000
Market Cap: $5.59 million
Optionable: Not Optionable
Beta: 3.52

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Terrence W. Norchi M.D. (Age 59)
Co-Founder, Chairman, President & CEO
Comp: $450.5k
Mr. Michael S. Abrams (Age 54)
CFO & Treasurer
Comp: $325k
Dr. Rutledge Ellis-Behnke Ph.D.
Co-Founder & Scientific Advisor
Mr. Shawn Carlson
Vice President of Sales

Key Competitors

View All Competitors

ARTH Stock Analysis - Frequently Asked Questions

How have ARTH shares performed in 2024?: Arch Therapeutics' stock was trading at $7.24 on January 1st, 2024. Since then, ARTH stock has decreased by 85.5% and is now trading at $1.05.
View the best growth stocks for 2024 here.
When is Arch Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ARTH earnings forecast.
How were Arch Therapeutics' earnings last quarter?: Arch Therapeutics, Inc. (OTCMKTS:ARTH) released its quarterly earnings data on Tuesday, February, 20th. The biotechnology company reported ($0.57) earnings per share for the quarter. The biotechnology company had revenue of $0.05 million for the quarter.

What other stocks do shareholders of Arch Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arch Therapeutics investors own include Anavex Life Sciences (AVXL), POET Technologies (POETF), Aptose Biosciences (APTO), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), SCYNEXIS (SCYX), Bellerophon Therapeutics (BLPH), Sorrento Therapeutics (SRNE), Biocept (BIOC) and Aurinia Pharmaceuticals (AUPH).
How do I buy shares of Arch Therapeutics?: Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ARTH) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial